Evidence map›Paper›PMID 39975434›Full record

ArticleArXiv2025

A Network-Driven Framework for Enhancing Gene-Disease Association Studies in Coronary Artery Disease.

Gutama Ibrahim Mohammad, Johan Lm Björkegren, Tom Michoel

Abstract readPreprint
In one paragraph

Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gutama Ibrahim MohammadComputational Biology Unit, Department of Informarics, University of Bergen, Norway.
Johan Lm BjörkegrenDepartment of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden.
Tom MichoelComputational Biology Unit, Department of Informarics, University of Bergen, Norway.

Funding

Multimodal genetic regulatory architecture of coronary artery diseaseR01HL148239 · NHLBI · UNIVERSITY OF VIRGINIA · PI Clint L Miller · 2019 to 2026
$4.2M
Integrative genomic and functional genomic studies to connect variant to function for CAD GWAS lociR01HL168174 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Wei Li, EDOARDO MARCORA · 2023 to 2026
$3.1M
Understanding the Molecular Mechanisms of Fibromuscular DysplasiaR01HL148167 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KADIAN-DODOV, DANIELLA, KOVACIC, JASON CIRIL · 2020 to 2023
$2.8M
Systems Genetics of Vascular Smooth Muscle PhenotypesR01HL166428 · NHLBI · UNIVERSITY OF VIRGINIA · PI Mete Civelek · 2023 to 2026
$2.4M
Functional genomics investigation of pleiotropic vascular disease lociR01HL164577 · NHLBI · UNIVERSITY OF VIRGINIA · PI MILLER, CLINT L · 2022 to 2025
$2.3M
NHLBI NIH HHS R01 HL148167NHLBI NIH HHS R01 HL148239NHLBI NIH HHS R01 HL164577NHLBI NIH HHS R01 HL166428NHLBI NIH HHS R01 HL168174
6 · The paper itself

Abstract

Motivation: Over the last decade, genome-wide association studies (GWAS) have successfully identified numerous genetic variants associated with complex diseases. These associations have the potential to reveal the molecular mechanisms underlying complex diseases and lead to the identification of novel drug targets. Despite these advancements, the biological pathways and mechanisms linking genetic variants to complex diseases are still not fully understood. Most trait-associated variants reside in non-coding regions and are presumed to influence phenotypes through regulatory effects on gene expression. Yet, it is often unclear which genes they regulate and in which cell types this regulation occurs. Transcriptome-wide association studies (TWAS) aim to bridge this gap by detecting trait-associated tissue gene expression regulated by GWAS variants. However, traditional TWAS approaches frequently overlook the critical contributions of trans-regulatory effects and fail to integrate comprehensive regulatory networks. Here, we present a novel framework that leverages tissue-specific gene regulatory networks (GRNs) to integrate cis- and trans-genetic regulatory effects into the TWAS framework for complex diseases. Results: We validate our approach using coronary artery disease (CAD), utilizing data from the STARNET project, which provides multi-tissue gene expression and genetic data from around 600 living patients with cardiovascular disease. Preliminary results demonstrate the potential of our GRN-driven framework to uncover more genes and pathways that may underlie CAD. This framework extends traditional TWAS methodologies by utilizing tissue-specific regulatory insights and advancing the understanding of complex disease genetic architecture. Availability: https://github.com/guutama/GRN-TWAS.

Identifiers

PMID39975434
PMCPMC11838773

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.